FrancophonIA/ELRC3.0 huggingface dataset:
English: In another monotherapy study in mild to moderate Alzheimer's disease a total of 470 patients (MMSE total scores at baseline of 11-23) were randomised.
Estonian: Teises kerge kuni mõõduka raskusega Alzheimeri tõve monoteraapia randomiseeritud uuringus oli 470 patsienti (MMSE algskooridega 11…23).
English: - The other ingredients are microcrystalline cellulose, croscarmellose sodium, magnesium stearate, talc and colloidal anyhdrous silica, all in the tablet core; polydextrose (E1200), titanium dioxide (E171), hypromellose 3cP (E464), hypromellose 6cP (E464), hypromellose 50cP (E464), iron oxide yellow (E172), macrogol 400 (E1521), macrogol 8000, indigo carmine aluminium lake (E132) and iron oxide red (E172), all in the tablet coating.
Estonian: - Teised koostisosad on mikrokristalliline tselluloos, naatriumkroskarmelloos, magneesiumstearaat, talk ja veevaba kolloidne ränidioksiid, mis sisalduvad tableti sisus; polüdekstroos (E1200), titaandioksiid (E171), hüpromelloos 3cP (E464), hüpromelloos 6cP (E464), hüpromelloos 50cP (E464), kollane raudoksiid (E172), makrogool 400 (E1521), makrogool 8000, indigokarmiin alumiiniumlakk (E132) ja punane raudoksiid (E172), mis sisalduvad tableti kattes.
English: The film-coated tablets can be taken with or without food.
Estonian: Õhukese polümeerikattega tablette võib võtta koos või ilma toiduta.
English: At a dose of memantine of 20 mg per day the CSF levels match the ki-value (ki = inhibition constant) of memantine, which is 0.5 μmol in human frontal cortex.
Estonian: Farmakokineetiline/farmakodünaamiline seos memantiini 20 mg päevaannuse puhul on ravimi sisaldus tserebrospinaalvedelikus võrdne memantiini ki-väärtusega (ki = inhibitsioonikonstant), mis inimese frontaalkorteksis on 0,5 mikromooli.
English: There are no or limited amount of data from the use of memantine in pregnant women.
Estonian: Memantiini kasutamise kohta rasedatel naistel andmed puuduvad või on piiratud.
English: Tablet cores for 10/20 mg film-coated tablets: Cellulose, microcrystalline Croscarmellose sodium Magnesium stearate
Estonian: 10/20 mg õhukese polümeerikattega tableti sisu: Mikrokristalliline tselluloos Naatriumkroskarmelloos Magneesiumstearaat
English: Standard clinical procedures to remove active substance material, e.g. gastric lavage, carbo medicinalis (interruption of potential entero-hepatic recirculation), acidification of urine, forced diuresis should be used as appropriate.
Estonian: Vajadusel tuleks rakendada toimeaine eemaldamiseks standardseid kliinilisi protseduure, st maoloputust, aktiivsütt (potentsiaalse enterohepaatilise ringe takistamine), uriini happeliseks muutmist, forsseeritud diureesi.
English: Fertility No adverse reactions of memantine were noted on male and female fertility.
Estonian: Fertiilsus Memantiini kasutamisel ei ole täheldatud kõrvaltoimeid meeste ega naiste fertiilsusele.
English: Memantine-treated patients showed a statistically significantly better effect than placebo-treated patients on the primary endpoints: Alzheimer´s disease assessment scale (ADAS-cog) (p=0.003) and CIBIC-plus (p=0.004) at week 24 (last observation carried forward (LOCF)).
Estonian: Esmased uuringu tulemused 24. nädalal pärast viimast tehtud hindamist (last observation carried forward (LOCF) memantiiniga ravitud patsientidel on näidanud statistiliselt oluliselt paremat toimet, kui platseebot saanud patsientidel järgmiste testide osas - Alzheimeri tõve hindamise skaala (ADAS-cog) (p=0,003) ja CIBIC-plus (p=0,004).
English: The pack sizes 28 x 1, 56 x 1, 98 x 1 and 100 x 1 film-coated tablets are presented in unit dose blisters.
Estonian: Pakendi suurused 28 × 1, 56 × 1, 98 × 1 ja 100 × 1 õhukese polümeerikattega tabletti tarnitakse blisterpakendites.
English: In patients with moderate renal impairment (creatinine clearance 30 - 49 ml/min) daily dose should be 10 mg per day.
Estonian: Mõõduka neerukahjustusega patsientidel (kreatiniini kliirens 30…49 ml/min) tuleb ööpäevast annust vähendada 10 mg-ni.
English: - If you take a large overdose of Memantine Mylan, contact your doctor or get medical advice, as you may need medical attention.
Estonian: - Suure üleannustamise korral kontakteeruge arstiga või pöörduge lähimasse haiglasse, kuna te võite vajada arstiabi.
English: A pivotal monotherapy study of memantine in the treatment of mild to moderate Alzheimer's disease (MMSE total scores at baseline of 10 to 22) included 403 patients.
Estonian: Kerge kuni mõõduka Alzheimeri tõve (MMSE algskooridega 10 kuni 22 punkti) memantiini olulise tähtsusega monoteraapia uuring hõlmas 403 patsienti.
English: How to store Memantine Mylan
Estonian: Kuidas Memantine Mylani säilitada
English: The following adverse reactions listed in the Table below have been accumulated in clinical studies with memantine and since its introduction in the market.
Estonian: Alljärgnevas tabelis on esitatud Memantine Mylani kliinilistes uuringutes ja turuletulekujärgselt kogunenud kõrvaltoimed.
English: Indigo carmine aluminium lake (E132)
Estonian: Kollane raudoksiid (E172) Indigokarmiin alumiiniumlakk (E132)
English: Administration of Memantine Mylan is not recommended in patients with severe hepatic impairment.
Estonian: Memantine Mylani manustamine raske maksakahjustusega patsientidel ei ole soovitatav.
English: Hypromellose 50cP (E464)
Estonian: Hüpromelloos 3cP (E464) Hüpromelloos 6cP (E464) Hüpromelloos 50cP (E464) Makrogool 400 (E1521)
English: How to take Memantine Mylan
Estonian: Kuidas Memantine Mylani kasutada
English: Each film-coated tablet contains 10 mg of memantine hydrochloride equivalent to 8.31 mg memantine.
Estonian: Üks õhukese polümeerikattega tablett sisaldab 10 mg memantiinvesinikkloriidi, mis vastab 8,31 mg memantiinile.
English: From Week 4 on: The patient should take two 10 mg film-coated tablets (20 mg) or one 20 mg film-coated tablet per day.
Estonian: Patsient peab võtma iga ööpäev kaks 10 mg õhukese polümeerikattega tabletti (20 mg) või ühe 20 mg õhukese polümeerikattega tableti.
English: Each film-coated tablet contains 20 mg of memantine hydrochloride equivalent to 16.62 mg memantine.
Estonian: Üks õhukese polümeerikattega tablett sisaldab 20 mg memantiinvesinikkloriidi, mis vastab 16.62 mg memantiinile.
English: • Tiredness, fungal infections, confusion, hallucinations, vomiting, abnormal gait, heart failure and venous blood clotting (thrombosis/thromboembolism)
Estonian: • Väsimus, seeninfektsioonid, segasus, hallutsinatsioonid, oksendamine, ebanormaalne kõnnak,
English: A pivotal monotherapy study in a population of patients suffering from moderate to severe Alzheimer's disease (mini mental state examination (MMSE) total scores at baseline of 3 - 14) included a total of 252 outpatients.
Estonian: Mõõduka kuni raske Alzheimeri tõvega (MMSE (mini mental state examination) algskoor 3…14) patsientide grupi olulise tähtsusega monoteraapia uuringus osales kokku 252 ambulatoorset patsienti.
English: What Memantine Mylan looks like and contents of the pack A red film-coated, oval, biconvex, beveled edge tablet marked with “ME” on one side of the tablet and “20” on the other side.
Estonian: Kuidas Memantine Mylan välja näeb ja pakendi sisu Punane õhukese polümeerikattega ovaalne kaksikkumer kaldservadega tablett, mille ühel küljel on pimetrükk „ME“ ja teisel küljel „20“.
English: Titanium dioxide (E171)
Estonian: 10 mg õhukese polümeerikattega tablett sisaldab ka: Titaandioksiid (E171)
English: Tel: + 39 02 612 46921
Estonian: Mylan S.p.A Tel: + 39 02 612 46921
English: These events have been reported in patients treated with memantine hydrochloride.
Estonian: Memantiinvesinikkloriidiga ravitud patsientidel on neist juhtudest teatatud.
English: What Memantine Mylan looks like and contents of the pack A dark yellow film-coated, tapered oblong shaped, biconvex tablet marked with “ME” on the left of the score and “10” on the right of the score on one side of the tablet and a score on the other side.
Estonian: Kuidas Memantine Mylan välja näeb ja pakendi sisu Tumekollane õhukese polümeerikattega teravate otstega piklik kaksikkumer tablett, mille ühel küljel on poolitusjoonest vasakulpimetrükk „ME“ ja paremal „10“ ning teisel küljel on poolitusjoon.
English: • There may be a possibility of reduced serum level of hydrochlorothiazide (HCT) when memantine is coadministered with HCT or any combination with HCT.
Estonian: • Memantiini manustamisel koos hüdroklorotiasiidi või mõne hüdroklorotiasiidi sisaldava kombineeritud preparaadiga võib väheneda hüdroklorotiasiidi sisaldus seerumis.
English: • Inflammation of the pancreas, inflammation of the liver (hepatitis) and psychotic reactions Alzheimer's disease has been associated with depression, suicidal ideation and suicide.
Estonian: • Kõhunäärme põletik, maksapõletik (hepatiit) ja psühhootilised reaktsioonid.
English: 84 film-coated tablets
Estonian: 84 õhukese polümeerikattega tabletti.
English: one and a half 10 mg tablets week 4 and beyond two 10 mg tablets once a day
Estonian: 4. nädal ja edasi kaks 10 mg tabletti üks kord ööpäevas
English: In order to reduce the risk of side effects this dose is achieved gradually by the following daily treatment scheme.
Estonian: Kõrvaltoimete riski vähendamiseks saavutatakse see annus igapäevast raviskeemi järgides järk-järgult: Üles tiitrimiseks on saadaval eri tugevustega tabletid.
English: • Headache, sleepiness, constipation, elevated liver function tests, dizziness, balance disorders, shortness of breath, high blood pressure and drug hypersensitivity
Estonian: • Peavalu, unisus, kõhukinnisus, maksafunktsiooni näitajate tõus, pearinglus, tasakaaluhäired,
English: 70 film-coated tablets
Estonian: 70 õhukese polümeerikattega tabletid.
English: 42 film-coated tablets
Estonian: 42 õhukese polümeerikattega tabletid.
English: 7 film-coated tablets
Estonian: 7 õhukese polümeerikattega tabletti.
English: 56 x 1 film-coated tablets 60 film-coated tablets
Estonian: 56 × 1 õhukese polümeerikattega tabletid.
English: Elevated liver function test
Estonian: Maksafunktsiooni näitajate tõus
English: Week 1 (day 1-7): The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
Estonian: päev): Patsient peab võtma ööpäevas pool 10 mg õhukese polümeerikattega tabletist (5 mg) 7 päeva jooksul.
English: 56 film-coated tablets
Estonian: 56 õhukese polümeerikattega tabletid.
English: 14 film-coated tablets
Estonian: 14 õhukese polümeerikattega tabletid.
English: 28 film-coated tablets
Estonian: 28 õhukese polümeerikattega tabletid.
English: 10 film-coated tablets
Estonian: 10 õhukese polümeerikattega tabletti.
English: 50 film-coated tablets
Estonian: 50 õhukese polümeerikattega tabletid.
English: EU/1/13/827/007 42 film-coated tablets
Estonian: EU/1/13/827/007 42 õhukese polümeerikattega tabletid.
English: NAME OF THE MEDICINAL PRODUCT Memantine Mylan 10 mg film-coated tablets Memantine Mylan 20 mg film-coated tablets
Estonian: Memantine Mylan 10 mg õhukese polümeerikattega tabletid Memantine Mylan 20 mg õhukese polümeerikattega tabletid
English: If you have impaired kidney function, your doctor will decide upon a dose that suits your condition.
Estonian: Annustamine neerutalitluse häirega patsientidel Kui teil esineb neerutalitluse häire, määrab arst teile sobiva annuse.
English: A dark yellow film-coated, tapered oblong shaped, biconvex tablet debossed with “ME” on the left of the score and “10” on the right of the score on one side of the tablet and a score on the other side.
Estonian: Memantine Mylan 10 mg õhukese polümeerikattega tabletid Tumekollane õhukese polümeerikattega teravate otstega piklik kaksikkumer tablett, mille ühel küljel on poolitusjoonest vasakul pimetrükk „ME“ ja paremal „10“ ning teisel küljel on poolitusjoon.
English: EU/1/13/827/025 42 film-coated tablets
Estonian: EU/1/13/827/025 42 õhukese polümeerikattega tabletti.
English: EU/1/13/827/009 56 film-coated tablets
Estonian: EU/1/13/827/009 56 õhukese polümeerikattega tabletid.
English: EU/1/13/827/026 50 film-coated tablets
Estonian: EU/1/13/827/026 50 õhukese polümeerikattega tabletti.
English: one and a half 10 mg tablets week 4 and beyond one 20 mg tablet once a day
Estonian: 4. nädal ja edasi üks 20 mg tablett üks kord ööpäevas
English: EU/1/13/827/004 28 film-coated tablets
Estonian: EU/1/13/827/004 28 õhukese polümeerikattega tabletid.
English: NAME OF THE MEDICINAL PRODUCT Memantine Mylan 20 mg film-coated tablets memantine hydrochloride
Estonian: RAVIMPREPARAADI NIMETUS Memantine Mylan 20 mg õhukese polümeerikattega tabletid memantiinvesinikkloriid
English: EU/1/13/827/022 28 film-coated tablets
Estonian: EU/1/13/827/022 28 õhukese polümeerikattega tabletti.
English: NAME OF THE MEDICINAL PRODUCT Memantine Mylan 10 mg film-coated tablets memantine hydrochloride
Estonian: RAVIMPREPARAADI NIMETUS Memantine Mylan 10 mg õhukese polümeerikattega tabletid memantiinvesinikkloriid
English: Week 2 (day 8-14): The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days.
Estonian: päev): Patsient peab võtma ööpäevas ühe 10 mg õhukese polümeerikattega tableti (10 mg) 7 päeva jooksul.
English: EU/1/13/827/032 98 film-coated tablets
Estonian: EU/1/13/827/032 98 õhukese polümeerikattega tabletti.
English: EU/1/13/827/020 10 film-coated tablets
Estonian: EU/1/13/827/020 10 õhukese polümeerikattega tabletti.
English: EU/1/13/827/027 56 film-coated tablets
Estonian: EU/1/13/827/027 56 õhukese polümeerikattega tabletti.
English: EU/1/13/827/002 10 film-coated tablets
Estonian: EU/1/13/827/002 10 õhukese polümeerikattega tabletid.
English: EU/1/13/827/019 7 film-coated tablets
Estonian: EU/1/13/827/019 7 õhukese polümeerikattega tabletti.
English: 28 x 1 film-coated tablets 30 film-coated tablets
Estonian: 28 × 1 õhukese polümeerikattega tabletti.
English: EU/1/13/827/030 70 film-coated tablets
Estonian: EU/1/13/827/030 70 õhukese polümeerikattega tabletti.
English: Week 3 (day 15-21): The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days.
Estonian: Patsient peab võtma ööpäevas poolteist 10 mg õhukese polümeerikattega tabletti (15 mg) 7 päeva jooksul.
English: EU/1/13/827/031 84 film-coated tablets
Estonian: EU/1/13/827/031 84 õhukese polümeerikattega tabletti.
English: EU/1/13/827/008 50 film-coated tablets
Estonian: EU/1/13/827/008 50 õhukese polümeerikattega tabletid.
English: EU/1/13/827/012 70 film-coated tablets
Estonian: EU/1/13/827/012 70 õhukese polümeerikattega tabletid.
English: Memantine Mylan 20 mg film-coated tablets memantine hydrochloride
Estonian: Memantine Mylan 20 mg, õhukese polümeerikattega tabletid memantiinvesinikkloriid
English: EU/1/13/827/001 7 film-coated tablets
Estonian: EU/1/13/827/001 7 õhukese polümeerikattega tabletid.
English: EU/1/13/827/014 98 film-coated tablets
Estonian: EU/1/13/827/014 98 õhukese polümeerikattega tabletid.
English: Memantine Mylan 10 mg film-coated tablets memantine hydrochloride
Estonian: Memantine Mylan 10 mg, õhukese polümeerikattega tabletid memantiinvesinikkloriid
English: EU/1/13/827/013 84 film-coated tablets
Estonian: EU/1/13/827/013 84 õhukese polümeerikattega tabletid.
English: In this case, monitoring of your kidney function should be performed by your doctor at specified intervals.
Estonian: Sellisel juhul kontrollib arst regulaarselt teie neerutalitlust.
English: EU/1/13/827/021 14 film-coated tablets
Estonian: EU/1/13/827/021 14 õhukese polümeerikattega tabletti.
English: EU/1/13/827/003 14 film-coated tablets
Estonian: EU/1/13/827/003 14 õhukese polümeerikattega tabletid.
English: EU/1/13/827/028 56 x 1 film-coated tablets EU/1/13/827/029 60 film-coated tablets
Estonian: EU/1/13/827/028 56 × 1 õhukese polümeerikattega tabletti.
English: Elderly
Estonian: Lineaarsus
English: EU/1/13/827/010 56 x 1 film-coated tablets EU/1/13/827/011 60 film-coated tablets
Estonian: EU/1/13/827/010 56 × 1 õhukese polümeerikattega tabletid.
English: EU/1/13/827/023 28 x 1 film-coated tablets EU/1/13/827/024 30 film-coated tablets
Estonian: EU/1/13/827/023 28 × 1 õhukese polümeerikattega tabletti.
English: EU/1/13/827/005 28 x 1 film-coated tablets EU/1/13/827/006 30 film-coated tablets
Estonian: EU/1/13/827/005 28 × 1 õhukese polümeerikattega tabletid.
English: PecFent received a marketing authorisation valid throughout the EU on 31 August 2010.
Estonian: PecFent on saanud müügiloa, mis kehtib kogu ELis, 31. augustil 2010.
English: What measures are being taken to ensure the safe and effective use of PecFent?
Estonian: Mis meetmed võetakse, et tagada PecFenti ohutu ja efektiivne kasutamine?
English: PecFent (fentanyl)
Estonian: PecFent (fentanüül)
English: Further information on PecFent can be found on the Agency's website: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Lisateave PecFenti kohta on ameti veebilehel: EMA website/Find medicine/Human medicines/European Public Assessment Reports.
English: This means that it is similar to ‘reference medicines' containing the same active substance, but given in a different way.
Estonian: See tähendab, et see on sarnane sama toimeainet sisaldava võrdlusravimiga, kuid seda manustatakse teistmoodi.
English: The average reduction in pain during the first 30 minutes after use was 6.6 points in patients receiving PecFent compared with 4.5 in those receiving placebo.
Estonian: Valu keskmine vähenemine esimese 30 minuti jooksul oli PecFenti kasutamisel 6,6 punkti ja platseebo kasutamisel 4,5 punkti.
English: As for all medicines, data on the use of PecFent are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse PecFenti kasutamise kohta pidevat järelevalvet.
English: Patients should not take more than four doses a day and should leave a gap of at least four hours between treating each episode of pain.
Estonian: Patsiendid ei tohi ööpäevas kasutada rohkem kui nelja annust ja iga valuepisoodi ravi vahele peab jääma vähemalt neli tundi.
English: The doses should be given as either one spray or two sprays of the same strength.
Estonian: Annus peab olema kas üks pihustus või kaks sama tugevusega pihustust.
English: The doctor should keep in mind the potential for PecFent to be abused.
Estonian: Arst peab arvesse võtma PecFenti kuritarvitamise potentsiaali.
English: The most serious of these side effects are respiratory depression (inhibition of breathing), circulatory depression (slow heartbeat), hypotension (low blood pressure) and shock (a steep fall in blood pressure).
Estonian: Neist kõrvalnähtudest kõige raskem on hingamisdepressioon (pärsitus), vereringe depressioon (aeglane südametegevus), hüpotensioon (madal vererõhk) ja šokk (järsk vererõhu langus).
English: Based on available data, the Agency concluded that PecFent's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Tuginedes olemasolevatele andmetele, otsustas Euroopa Ravimiamet, et PecFenti kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: What is PecFent and what is it used for?
Estonian: Mis on PecFent ja milleks seda kasutatakse?
English: What are the risks associated with PecFent?
Estonian: Mis riskid PecFentiga kaasnevad?
English: Because PecFent is a hybrid medicine, the applicant presented data on the reference medicines in addition to results from its own studies.
Estonian: Et PecFent on hübriidravim, esitas taotleja lisaks oma uuringutest saadud andmetele ka andmed võrdlusravimite kohta.
English: When a patient starts to take PecFent the doctor will need to work out the appropriate dose that will provide adequate pain relief with as few side effects as possible.
Estonian: Kui patsient alustab PecFenti võtmist, peab arst leidma patsiendi jaoks sobiva annuse, mis tagab valu adekvaatse leevendamise võimalikult väheste kõrvalnähtudega.
English: PecFent is available as a nasal spray (100 and 400 micrograms per spray) and can only be obtained by ‘special' prescription.
Estonian: PecFenti turustatakse ninaspreina (100 ja 400 g ühes pihustuses) ja on saadaval ainult eriretseptiga.
English: It must not be used to treat short-term pain other than breakthrough pain.
Estonian: Ravimit ei tohi kasutada muuks lühiajaliseks valuraviks peale läbimurdevalu ravi.
English: The company that markets PecFent will provide educational materials in each EU Member State to make sure that patients, doctors and pharmacists are aware of how PecFent should be used, the risk of accidental exposure to fentanyl and how to dispose of the medicine.
Estonian: PecFenti turustav ettevõte koostab kõigi ELi liikmesriikide jaoks teabematerjalid, et patsiendid, arstid ja apteekrid teaksid, kuidas PecFenti kasutada, missugused on fentanüüli juhusliku ekspositsiooniga seotud riskid ja kuidas ravimit hävitada.
English: PecFent must not be used in patients who are not already taking opioids to maintain pain control, who have severe respiratory depression (inhibition of breathing) or who have severe obstructive lung conditions (diseases that severely impede breathing).
Estonian: PecFenti ei tohi kasutada patsiendid, kes ei saa valuraviks opioidravi, kellel on raske hingamisdepressioon (pärsitus) või kellel on rasked obstruktiivsed kopsuhaigused (hingamist oluliselt takistavad haigused).
English: Other information about PecFent:
Estonian: Muu teave PecFenti kohta
English: Side effects reported with PecFent are carefully evaluated and any necessary action taken to protect patients.
Estonian: PecFenti kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of PecFent have also been included in the summary of product characteristics and the package leaflet.
Estonian: PecFenti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: PecFent is a ‘hybrid medicine'.
Estonian: PecFent on hübriidravim.
English: The main measure of effectiveness was the change in the severity of pain measured by the patients ranking their pain on a scale from 0 to 10.
Estonian: Efektiivsuse põhinäitaja oli patsientide määratud valu tugevus skaalal 0 kuni 10.
English: How is PecFent used?
Estonian: Kuidas PecFenti kasutatakse?
English: While the reference medicines Effentora (buccal tablets) and Actiq (lozenges) are taken by mouth, PecFent is given as a spray into the nose.
Estonian: Referentsravimeid Effentora (bukaaltabletid) ja Actiq (losengid) manustatakse suu kaudu, kuid PecFenti manustatakse spreina ninna.
English: PecFent is a medicine used to treat breakthrough pain in adult patients with cancer.
Estonian: PecFent on ravim, mida kasutatakse läbimurdevalu raviks täiskasvanud patsientidel, kellel on vähk.
English: For more information about using PecFent, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet PecFenti kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Breakthrough pain is when a patient experiences additional, sudden pain in spite of ongoing treatment with painkillers.
Estonian: Läbimurdevalu on selline täiendav ja äkiline valu, mida patsient tunneb vaatamata käimasolevale püsiravile valuvaigistitega.
English: When the patient sprays PecFent into the nose, a dose of fentanyl is rapidly absorbed into the blood stream through the blood vessels in the nose.
Estonian: Kui patsient pihustab PecFenti ninna, imendub fentanüüli annus ninas olevate veresoonte kaudu kiiresti vereringesse.
English: The European Medicines Agency noted that there was a need for fast-acting pain medicines for breakthrough pain in patients with cancer.
Estonian: Euroopa Ravimiamet märkis, et püsib vajadus kiiretoimeliste valuvaigistite järele vähiga patsientide läbimurdevalu ravis.
English: The patient should be monitored carefully while the dose is increased.
Estonian: Patsienti peab annuse suurendamise ajal hoolikalt jälgima.
English: This means that because the medicine can be misused or cause addiction, it is used under stricter conditions than normal.
Estonian: See tähendab, et seda ravimit kasutatakse rangemates tingimustes kui tavalisi ravimeid, sest ravim võib põhjustada kuritarvitamist või sõltuvust.